Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
dasatinib in chronic phase chronic mieloid leukemia patients with chronic toxicity to imatinib
The primary objective of this study is to assess the frequency of reduction in grade (Grade 2 to 1) or resolution of imatinib-related chronic Grade 1 or Grade 2 non-hematologic AEs within 3 months a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have An Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options. Revised Protocol 3, incorporating Amendments 2, 3 and 8. + Protocol Amendments 1 & 5. + Protocol Amendment 11 - Site specific: All sites in Belgium (v1.0, dated 23-Sep-2008)
Summarize incidence of adverse events/serious adverse events/discontinuations due to adverse events during 6 months of combined treatment with abatacept and 1 or more background non-biologic DMARDs ap...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma Revised Protocol 2, incorporating Amendments 2 and 7 - version 5.0, dated 28-Sep-07 + Protocol Amendment 01-Pharmacogenetics Blood Sample; + Protocol Amendment 03-Pharmacogenomics Tissue Sample; + Protocol Amendment 04-Pharmacogenomic Biomarker Sample. + Amendment 5 Country Specific - Germany - version 1.0, dated 04-Apr-06 + Amendment 6 Country Specific - Germany - version 1.0, dated 11-Aug-06
To estimate best overall response rate (BORR) (as per modified WHO criteria) in patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma recei...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
Nivolumab and ipilimumab in combination for lung cancer
To characterize the safety of nivolumab administered as a flat dose in combination with weight-based ipilimumab dosing in Cohorts A and B.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
Study of the Safety and Pharmacokinetics of apixaban versus warfarin or low molecular weight heparin in children with congenital or acquired heart disease that need anticoagulation
The objectives of this study are to assess the following in pediatric subjects with congenital or acquired heart disease requiring chronic prophylactic anticoagulation: *the safety of apixaban *a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras wild type Subjects with Metastatic Colorectal Cancer. Revised Protocol 03 (v5.0, dated 2 July 2008) incorporating Protocol Amendment 04 (v1.0, dated 2 July 2008). And Pharmacogenetics Blood Sample Amendment 01. Estudio fase 1/2, enmascarado y aleatorizado de brivanib alaninato frente a placebo en combinación con Erbitux e Irinotecán en sujetos con cáncer colorrectal metastásico con K-Ras de tipo natural. Protocolo revisado 03 (v5.0, 02-Julio-08) incorporando la enmienda al protocolo 04(v1.0, 2 -Julio- 2008) y enmienda 01 de muestra de sangre para farmacogénética
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux and irinotecan to K-Ras wild type subjects with advanced metastatic colorectal cancer (MC...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Clinical Trial to be conducted in many hospitals and in different countries with the medicinal substance Nivolumab as the only therapy in patients with Non-Small Cell Lung Cancer (NSCLC) who have received earlier cancer treatments
To determine the incidence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in subjects with advanced or metastatic SqNSCLC who progressed during or after at least 1 sys...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of Ipilimumab Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients with Unresectable Stage III or IV Malignant Melanoma Revised Protocol 03 Incorporating Amendment 02, 03 and 05 (version 1.0, dated 12-Mar-07) + Pharmacogenetics Blood Sample Amendment 01 - Site Specific (version 1.0 dated 01-Aug-05)
To estimate the rate of Grade 2+ diarrhea in patients treated with intravenous ipilimumab when given with either prophylactic oral budesonide (Entocort EC) or placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
To compare the efficacy, as measured by recurrence-free survival (RFS), provided by nivolumab plus ipilimumab versus ipilimumab alone and nivolumab alone in participants with completely resected stage...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 4 ans
A Phase III Multicenter, Randomized, Double-Blind, placebo-controlled Study to Assess short-term changes in synovitis and structural damage outcomes in subjects with active Rheumatoid Arthritis and inadequate response to Methotrexate, Treated with Abatacept versus Placebo on a Background Therapy with Methotrexate. Estudio de fase IIIB, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar los cambios a corto plazo en la sinovitis y el daño estructural en sujetos con artritis reumatoide activa y respuesta inadecuada al metotrexato tratados con abatacept frente a placebo más un tratamiento de fondo de metotrexato + Protocol Amendment 01 (Version 1.0, Dated 16-May-2007) and Administrative Letter (Version 1.0, Dated 13-Jun-2007)
The primary objective of this study in subjects with active RA and inadequate response to MTX is to assess changes in wrist synovitis as measured by gadolinium-enhanced Magnetic Resonance Imaging (MRI...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant